Endometriosis: in search of optimal treatment.

W B Nothnick
Minerva ginecologica · 2010 · vol. 62(1) , pp. 17–31 · PMID:20186112 · W111506442
article OA: closed CC0 ⤵ 14 in-corpus citations
View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-22 ⓘ

This review discusses current hypoestrogenic treatments for endometriosis, their side effects and limitations, and explores potential alternative therapies like aromatase inhibitors and angiogenesis disruptors.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Endometriosis is an enigmatic, debilitating disease which affects as many as 15% of all women of reproductive age and is characterized by pelvic pain and infertility. Current treatment regimes used to manage the disease do so by inducing a hypoestrogenic state. While the absence of circulating estrogen levels lead to a regression of the disease, this hypoestrogenism also induces many unpleasant and unwanted side-effects. As such, these and other shortcomings of current drug therapies emphasize their limitations and the necessity for the development of novel endometriosis treatments. In this review, current therapies for medical management of endometriosis are discussed as are their shortcomings. Potential target areas which may be attractive alternatives to current therapies are also reviewed and include aromatase inhibitors, angiogenesis disruptors and anti-tumor necrosis factor-alpha inhibitors.

My notes (saved in your browser only)

Condition tags

endometriosisinfertility

MeSH descriptors

Endometriosis Adalimumab Anastrozole Angiogenesis Inhibitors Angiogenesis Inhibitors Antibodies, Monoclonal Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Anti-Inflammatory Agents, Non-Steroidal Anti-Inflammatory Agents, Non-Steroidal Aromatase Inhibitors Aromatase Inhibitors Endometriosis Endometriosis Estrogen Receptor Modulators Estrogen Receptor Modulators Estrogen Receptor Modulators Etanercept Female Gonadotropin-Releasing Hormone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (14)

SciLite annotations

chemicals 1
estrogen

Source provenance

europepmc
last seen: 2026-06-30T06:11:02.404677+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:17:18.915199+00:00
scilite
last seen: 2026-05-18T04:25:29.313245+00:00
License: CC0 · commercial use OK